The use of the new oral antifungal agents, itraconazole, terbinafine, and fluconazole, to treat onychomycosis and other dermatomycoses

Current Problems in Dermatology

Volumn 13, Issue 4, 2001, Pages 213-246

  Gupta, Aditya K ^a   Albreski, Douglas ^a   Del Rosso, James Q ^a   Konnikov, Nellie ^a  

^a UNIVERSITY OF TORONTO   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIFUNGAL AGENT; ASTEMIZOLE; CISAPRIDE; CYCLOSPORIN; DIGOXIN; DOFETILIDE; FELODIPINE; FLUCONAZOLE; ITRACONAZOLE; MEVINOLIN; MIDAZOLAM; NIFEDIPINE; NORTRIPTYLINE; ORAL ANTIDIABETIC AGENT; PHENYTOIN; PIMOZIDE; QUINIDINE; SIMVASTATIN; SULFONYLUREA DERIVATIVE; TERBINAFINE; TERFENADINE; TRIAZOLAM; WARFARIN;

DERMATOMYCOSIS; DRUG BIOAVAILABILITY; DRUG CONTRAINDICATION; DRUG INDICATION; DRUG INDUCED DISEASE; DRUG RESPONSE; DRUG SAFETY; FLOW CYTOMETRY; FUNGUS CULTURE; GASTROINTESTINAL SYMPTOM; HISTOPATHOLOGY; HUMAN; IMMUNOHISTOCHEMISTRY; NEUROLOGIC DISEASE; ONYCHOMYCOSIS; PATIENT COMPLIANCE; REINFECTION; RELAPSE; REVIEW; SKIN MANIFESTATION;

EID: 0034879198     PISSN: 10400486     EISSN: None     Source Type: Journal    
DOI: 10.1067/mdm.2001.108128     Document Type: Article

References (312)

1. Prevalence and epidemiology of unsuspected onychomycosis in patients visiting dermatologists' offices in Ontario, Canada - A multicenter survey of 2001 patients
2. Autosomal dominant pattern of distal subungual onychomycosis caused by Trichophyton rubrum
3. Studies in the epidemiology of tinea pedis II: Dermatophytes on the floors of swimming-baths
4. Studies in the epidemiology of tinea pedis VII: The circulation of infection
5. Foot ringworm in coal-miners
6. Common superficial fungal infections in patients with AIDS
7. Dermatologic findings associated with human immunodeficiency virus infection
8. Prevalence and epidemiology of toenail onychomycosis in diabetic subjects: A multicentre survey
9. Onychomycosis
10. A new classification of onychomycosis
11. Onychomycosis and its treatment
12. Candida onychomycosis - An evaluation of the role of Candida species in nail disease
13. Uncommon clinical patterns of Fusarium nail infection: Report of three cases
14. Onychomycosis due to Scopulariopsis brevicaulis: Clinical features and response to systemic antifungals
15. Proximal subungual onychomycosis due to Microsporum canis
16. Proximal subungual Candida onychomycosis: An unusual manifestation of chronic mucocutaneous candidosis
17. Proximal white subungual onychomycosis in AIDS
18. Proximal white subungual onychomycosis in a patient with acquired immune deficiency syndrome
19. Clinical pearl: Proximal white subungual onychomycosis in AIDS
20. Proximal white subungual onychomycosis: A sign of immunodeficiency
21. Onychomycosis and AIDS. Clinical and laboratory findings in 62 patients
22. White nails in AIDS/ARC due to Trichophyton rubrum infection
23. Proximal white subungual onychomycosis in the immunocompetent patient: Report of two cases and review of the literature
24. Proximal white subungual onychomycosis in a kidney transplant patient
25. Proximal subungual onychomycosis due to Aspergillus niger: Report of two cases
26. Onychomycosis provoked by moulds
27. Melanonychies superficielles
28. Onychomycosis due to Hendersonula toruloidea
29. "Endonyx" onychomycosis: A new modality of nail invasion by dermatophytes
30. Childhood injuries from artificial nail primer cosmetic products
31. Adverse contact reactions to sculptured acrylic nails: 4 Case reports and a literature review
32. Nail cosmetics
33. Onycholysis: An overview
34. Primary onycholysis of the big toenails: A review of 113 cases
35. Erythropoietic protoporphyria with onycholysis
36. Photo-onycholysis caused by demethylchlortetracycline
37. Permanent nail changes following gold therapy
38. Onycholysis due to acrylic nail applications
39. Photo-onycholysis caused by tetracyclines
40. Onycholysis in hyperthyroidism and hypothyroidism
41. Doxorubicin toxicity: Onycholysis, plantar callus formation and epidermolysis
42. Fungal vs drug-induced onycholysis
43. Hypoplastic enamel, onycholysis and hypohidrosis inherited as an autosomal dominant trait: A review of ectodermal dysplasia syndromes
44. Onycholysis in thyroid disease
45. Psoriasis of the nail: A clinical-pathologic study
46. Psoriasis and the nails
47. The nail in dermatological disease
48. Subtle clues to diagnosis from biopsies of nails: Histologic differential diagnosis of onychomycosis and psoriasis of the nail unit from cornified cells of the nail bed alone
49. Nail lichen planus: Clinical and pathological study of twenty-four patients
50. Lichen planus limited to the nails
51. Lichen planus limited to the nails
52. Lichen planus limited to the nails in childhood: Case report and literature review
53. The nails in lichen planus
54. Nail in lichen planus
55. The nail in Darier's disease
56. Darier's disease
57. Foot infections in patients with diabetes
58. Lower-extremity amputation in people with diabetes
59. Purpura, pigmentation and yellow nails of the lower extremities in diabetics
60. Nail changes secondary to systemic drugs and ingestants
61. The nail in systemic diseases and drug-induced changes
62. Antifungal agents: An overview. Part I
63. Onychomycosis: An evaluation of three sampling methods
64. The diagnosis of nail fungal infection
65. The dermatophytes
66. Management of onychomycosis: A North American perspective
67. Diagnostic techniques for confirming onychomycosis
68. Dermatophytes and agents of superficial mycoses
69. Superficial and cutaneous infections caused by molds: Dermatophytoses
70. Isolation and recognition of dermatophytes on a new medium (DTM)
71. Histologic evaluation of nail clippings for diagnosing onychomycosis
72. Routine histologic examination for the diagnosis of onychomycosis: An evaluation of sensitivity and specificity
73. Hyphae on the ventral nail plate as a clue to onychomycosis
74. Present and potential diagnostic techniques in onychomycosis
75. Fungi in onychomycosis: A study by immunohistochemistry and dual flow cytometry
76. Antifungal agents: An overview: Part II
77. Terbinafine for the treatment of pedal onychomycosis: A foot closer to the promised land of cured nails?
78. Current management of onychomycosis: An overview
79. Itraconazole pulse therapy for onychomycosis and dermatomycoses: An overview
80. Terbinafine: An update
81. Itraconazole for the treatment of onychomycosis
82. Onychomycosis: Pathogenesis, diagnosis and management
83. Onychomycosis: Agents of choice
84. New approaches to the treatment of onychomycosis
85. Risk/benefit ratio of modern antifungal therapy: Focus on hepatic reactions
86. Treatment of onychomycosis: Traditional approaches
87. Kinetics and spectrum of activity of oral antifungals: The therapeutic implications
88. Safety of oral terbinafine for toenail onychomycosis
89. Influence of concomitant food intake on the oral absorption of two triazole antifungal agents, itraconazole and fluconazole
90. Food interactions and steady-state pharmacokinetics of itraconazole capsules in healthy male volunteers
91. Pharmacokinetics of itraconazole following oral administration to normal volunteers
92. Itraconazole: Pharmacokinetics and indications
93. The pharmacokinetics of oral itraconazole in AIDS patients
94. Fluconazole: Pharmacokinetics and indications
95. Effect of oral antacid administration on the pharmacokinetics of oral fluconazole
96. Clinical pharmacology of fluconazole
97. Pharmacokinetics and tissue penetration of fluconazole in humans
98. An assessment of the effects of impaired renal function and haemodialysis on the pharmacokinetics of fluconazole
99. Clinical pharmacokinetics of terbinafine (Lamisil)
100. Terbinafine. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic potential in superficial mycoses
101. Multiple-dose pharmacokinetics and distribution in tissue of terbinafine and metabolites
102. Pharmacokinetics of oral antifungal agents
103. Pharmacokinetics of three doses of once-weekly fluconazole (150, 300 and 450 mg) in the management of distal subungual onychomycosis of the toenail
104. Systemic treatment of skin candidosis: A randomized comparison of terbinafine and ketoconazole
105. Nail incorporation kinetics of terbinafine in onychomycosis patients
106. Pharmacokinetic evaluation of fluconazole in skin and nails
107. Pharmacokinetic evaluation of fluconazole in plasma, epidermis and blister fluid
108. Levels of fluconazole in serum, stratum corneum, epidermis-dermis (without stratum corneum) and eccrine sweat
109. Itraconazole
110. Terbinafine
111. Fluconazole
112. Pharmacokinetic profile of orally administered itraconazole in human skin
113. Itraconazole pulse therapy is effective in the treatment of Majocchi's granuloma: A clinical and pharmacokinetic evaluation and implications for possible effectiveness in tinea capitis
114. How orally administered terbinafine reaches the stratum corneum
115. Terbinafine levels in serum, stratum corneum, dermis-epidermis (without stratum corneum), hair, sebum and eccrine sweat
116. Levels of terbinafine in plasma, stratum corneum, dermis-epidermis (without stratum corneum), sebum, hair and nails during and after 250 mg terbinafine orally once per day for four weeks
117. Levels of terbinafine in plasma, stratum corneum, dermis-epidermis (without stratum corneum), sebum, hair and nails during and after 250 mg terbinafine orally once daily for 7 and 14 days
118. Bioavailability of fluconazole in the skin after oral medication
119. Accumulation of fluconazole in scalp hair
120. The spectrum of utility of oral antifungal agents: From the Petri dish to the patient
121. Itraconazole in the treatment of superficial cutaneous and mucosal Candida infections
122. A double-blind, randomized, placebo-controlled evaluation of short-term treatment with oral itraconazole in patients with tinea versicolor
123. Itraconazole in tinea versicolor: A review
124. The use of intermittent itraconazole therapy for superficial mycotic infections: A review and update on the “one week" approach
125. The clinical use of itraconazole in superficial and deep mycoses
126. Advances in the treatment of superficial fungal infections: Focus on onychomycosis and dry tinea pedis
127. Recalcitrant dermatophyte infection
128. Itraconazole in the treatment of tinea corporis and tinea cruris
129. Short treatment schedules of itraconazole in dermatophytosis
130. Short term itraconazole versus terbinafine in the treatment of superficial dermatomycosis of the glabrous skin (tinea corporis or cruris)
131. Management of fungal skin infections with 15 days itraconazole treatment: A worldwide review
132. Itraconazole for the treatment of tinea pedis: A dosage of 400 mg/day given for 1 week is similar in efficacy to 100 or 200 mg/day given for 2 to 4 weeks
133. Short-term itraconazole versus terbinafine in the treatment of tinea pedis or manus
134. Itraconazole in common dermatophyte infections of the skin: Fixed treatment schedules
135. Itraconazole, a new orally active antifungal in the treatment of pityriasis versicolor
136. Itraconazole in the treatment of human mycoses: Review of three years of clinical experience
137. Randomized, comparative clinical trial of itraconazole and selenium sulfide shampoo for the treatment of pityriasis versicolor
138. Post treatment itraconazole levels in the nail
139. Antifungal pulse therapy for onychomycosis: A pharmacokinetic and pharmacodynamic investigation of monthly cycles of 1-week pulse therapy with itraconazole
140. Itraconazole pulse therapy vs terbinafine continuous dosing for toenail onychomycosis
141. The new oral antifungal agents for onychomycosis of the toenails: A review
142. A risk-benefit assessment of the newer oral antifungal agents used to treat onychomycosis
143. Itraconazole in onychomycosis: Intermittent dose schedule
144. Pulse therapy with one-week itraconazole monthly for three or four months in the treatment of onychomycosis
145. Double blind randomized study of continuous terbinafine compared with intermittent itraconazole in treatment of toenail onychomycosis
146. An intermittent itraconazole 1-week dosing regimen for the treatment of toenail onychomycosis in dermatological practice
147. The safety and efficacy of intermittent therapy with itraconazole for finger- and toenail onychomycosis: A multicenter trial
148. A double-blind, randomized study comparing itraconazole pulse therapy with continuous dosing for the treatment of toe-nail onychomycosis
149. Treatment of dermatophyte nail infections: An open randomized study comparing intermittent terbinafine therapy with continuous terbinafine treatment and intermittent itraconazole therapy
150. Therapeutic efficacy and safety of 1-week intermittent therapy with itraconazole for onychomycosis in a Chinese patient population
151. Small-dose itraconazole pulse therapy in the treatment of onychomycosis
152. Itraconazole therapy is effective for pedal onychomycosis caused by some nondermatophyte molds and with mixed infection with dermatophytes and molds: A multicenter study in 36 patients
153. Efficacy and tolerability of itraconazole in patients with fingernail onychomycosis: A 6-week pilot study
154. Itraconazole one week pulse therapy in the management of Candida paronychia
155. Fluconazole for the treatment of onychomycosis: An update
156. Treatment of pityriasis versicolor with a single dose of fluconazole
157. Once weekly oral doses of fluconazole 150 mg in the treatment of tinea corporis/cruris and cutaneous candidiasis
158. A multicentre (double-blind) comparative study to assess the safety and efficacy of fluconazole and griseofulvin in the treatment of tinea corporis and tinea cruris
159. Fluconazole in the treatment of tinea corporis and tinea cruris
160. Itraconazole versus fluconazole a double-blind comparison in tinea corporis
161. Efficacy and safety of oral fluconazole in the treatment of patients with tinea corporis, cruris or pedis or cutaneous candidiasis: A multicentre, open, non-comparative study
162. A comparison of the efficacy of oral fluconazole, 150 mg/week versus 50 mg/day, in the treatment of tinea corporis, tinea cruris, tinea pedis, and cutaneous candidosis
163. Once-weekly oral doses of fluconazole 150 mg in the treatment of tinea pedis
164. Fluconazole versus itraconazole in the treatment of tinea versicolor
165. Fluconazole in the treatment of tinea versicolor
166. An open-label, non-comparative, multicenter evaluation of fluconazole with or without urea nail pedicure for treatment of onychomycosis
167. Fluconazole in the treatment of onychomycosis caused by dermatophytes
168. Fluconazole in the treatment of severe onychomycosis
169. Once-weekly fluconazole (150 mg, 300 mg, or 450 mg) in the treatment of distal subungual onychomycosis of the toenail
170. The study to compare the efficacy of Lamisil (terbinafine) and Diflucan (fluconazole) in patients with onychomycosis. Poster 132
171. A comparison of the efficacy of oral griseofulvin, fluconazole and terbinafine in the treatment of onychomycosis
172. New strategies in the management of onychomycosis
173. Oral terbinafine versus griseofulvin in the treatment of moccasin-type tinea pedis
174. A comparative study of terbinafine versus griseofulvin in “dry type" dermatophyte infections
175. Successful treatment of chronic tinea pedis (moccasin-type) with terbinafine (Lamisil)
176. Terbinafine (Lamisil) versus griseofulvin in moccasin type tinea pedis
177. Successful 2-week treatment with terbinafine (Lamisil) for moccasin tinea pedis and tinea manuum
178. Two-week oral treatment of tinea pedis, comparing terbinafine (250 mg/day) with itraconazole (100 mg/day): A double-blind, multicentre study
179. A comparison of 2 weeks of terbinafine 250 mg/day with 4 weeks of itraconazole 100 mg/day in plantar-type tinea pedis
180. Short-term itraconazole versus terbinafine in the treatment of tinea pedis or manus
181. A comparison of a new oral antifungal, terbinafine, with griseofulvin as therapy for tinea corporis
182. A comparative double-blind study of terbinafine (Lamisil) and griseofulvin in tinea corporis and tinea cruris
183. One-week therapy with oral terbinafine in cases of tinea cruris/corporis
184. Short-term itraconazole versus terbinafine in the treatment of superficial dermatomycosis of the glabrous skin (tinea corporis or cruris)
185. A randomized double-blind multicentre comparative study of Lamisil (terbinafine) versus ketoconazole in tinea corporis
186. Intermittent therapy with terbinafine for dermatophyte toe-onychomycosis: A new approach
187. Open randomized comparison of itraconazole versus terbinafine in onychomycosis
188. Randomised double blind comparison of terbinafine and itraconazole for treatment of toenail tinea infection - Seventh Lamisil German Onychomycosis Study Group
189. A 12-week treatment for dermatophyte toe onychomycosis: Terbinafine 250mg/day vs. itraconazole 200mg/day - A double-blind comparative trial
190. Onychomycosis treated with a short course of oral terbinafine
191. Short term treatment of dermatophyte onychomycosis with terbinafine
192. Itraconazole versus terbinafine (Lamisil): Which is better for the treatment of onychomycosis?
193. Oral terbinafine in toenail dermatophytosis
194. Evaluation of 6 weeks treatment of terbinafine in tinea unguium in a double-blind trial comparing 6 and 12 weeks therapy - The Lagos V Study Group
195. Long-term post-treatment follow-up of onychomycosis treated with terbinafine: A multicentre trial
196. A randomized treatment duration-finding study of terbinafine in onychomycosis
197. Terbinafine in onychomycosis of the toenail: A novel treatment protocol
198. Treatment of Candida nail infection with terbinafine
199. Terbinafine in chronic paronychia and Candida onychomycosis
200. Systemic treatment of skin candidosis: A randomized comparison of terbinafine and ketoconazole
201. Terbinafine in onychomycosis with involvement by nondermatophytic fungi
202. Onychomycosis due to Scopulariopsis: Clinical features and response to systemic antifungals
203. Terbinafine in the treatment of Majocchi's granuloma
204. A double-blind, randomized, stratified, controlled study of the treatment of tinea imbricata with oral terbinafine or itraconazole
205. Treatment of cutaneous sporotrichosis with terbinafine
206. Black piedra: The first case treated with terbinafine (Lamisil)
207. Onychomycosis: Predisposed populations and some predictors of suboptimal response to oral antifungal agents
208. Prevalence of dermatophyte onychomycosis in the United Kingdom: Results of an omnibus survey
209. Prevalence of dermatophyte onychomycosis in Spain, a cross-sectional study
210. Prevalence of onychomycosis in patients attending a dermatology clinic in Northeastern Ohio for other conditions
211. Dermatophyte-hormone relationships: Characterization of progesterone - Binding specificity and growth inhibition in the genera Trichophyton and Microsporum
212. Itraconazole oral solution for the treatment of onychomycosis
213. The prevalence of onychomycosis in children and treatment strategies
214. A statistical analysis of a pediatric dermatology clinic
215. Dermatophyte onychomycosis in children
216. Tinea pedis as a public health problem
217. Incidence of occult athlete's foot in swimmers
218. Foot infection in coal miners: A reassessment
219. Studies in the epidemiology of tinea pedis - VIII: Fungal infection in a long-stay hospital
220. An experimental study of tinea pedis and onychomycosis of the foot
221. Immune response and host resistance of humans to dermatophyte infections
222. Suppression of immunity and inflammation by products produced by dermatophytes
223. Immunological reactivity in dermatophytosis
224. Diagnois: Tinea circinate and onychomycosis (Trichophyton purpureum) - Resistance to griseofulvin during uncontrolled diabetes
225. Recurrent Cushing's syndrome with Trichophyton rubrum infection
226. Generalized Trichophyton rubrum infection associated with systemic lymphoblastoma
227. Immune responses in patients with chronic Trichophyton rubrum infections
228. The spectrum of disease in patients with human immunodeficiency virus infection
229. A higher prevalence of onychomycosis in psoriatics compared with non-psoriatics: A multicenter study
230. Lateral edge nail involvement indicates poor prognosis for treating onchomycosis with the new systemic antifungals
231. Are local and systemic conditions important for the development of onychomycosis?
232. Factors that may affect the response of onychomycosis to oral antifungal therapy
233. Onychomycosis: Strategies to reduce failure, and recurrence
234. Subungual dermatophytoma complicating dermatophyte onychomycosis
235. Safety of oral terbinafine for toenail onychomycosis
236. How to recognize and manage adverse reactions to oral antifungals
237. Safety of oral terbìnafine: Results of a postmarketing surveillance study in 25,884 patients
238. Postmarketing surveillance of oral terbinafine in the UK: Report of a large cohort study
239. Taste loss to terbinafine: A case-control study of potential risk factors
240. Adverse drug reactions of the new oral antifungal agents - Terbinafine, fluconazole and itraconazole
241. An overview and an assessment of the use of the antifungal agents itraconazole, terbinafine and fluconazole in dermatology
242. Safety review of the new oral antifungal agents to treat superficial mycoses
243. A questionnaire study on the management of onychomycosis: Canadian perspective
244. Oral antifungal drug interactions
245. Drug interactions with itraconazole, fluconazole and terbinafine, and their management
246. Lower-extremity amputation in people with diabetes. Epidemiology and prevention
247. Reduction of lower extremity clinical abnormalities in patients with non-insulin dependent diabetes mellitus
248. Bone and soft-tissue infections of the lower extremity in diabetics
249. The economic costs of non-insulin-dependent diabetes mellitus
250. Incidence of lower limb amputations and diabetes
251. The prevalence of cutaneous manifestations in IDDM patients and their association with diabetes risk factors and microvascular complications
252. The prevalence and nature of podiatric problems in elderly diabetic patients
253. Tinea pedis
254. Interdigital athlete's foot: New concepts in pathogenesis
255. Interdigital athlete's foot. The interaction of dermatophyte and resident bacteria
256. Microbial ecology of interdigital infections of the toe web spaces
257. Dermatophyte feet infection among students enrolled in swimming courses at a university pool
258. Association of athlete's foot with cellulitus of the lower extremities: Diagnostic value of bacterial cultures of ipsilateral interdigital space samples
259. Ciclopiroxolamine lotion 1%: Bioequivalence to ciclopiroxolamine cream 1% and clinical efficacy in tinea pedis
260. Topical clotrimazole in tinea pedis
261. Topical terbinafine and clotrimazole in interdigital tinea pedis: A multicenter comparison of cure and relapse rates with 1- and 4- week treatment regimens
262. The antibacterial efficacy of econazole nitrate in interdigital toe web infections
263. An overview of topical antifungal therapy in dermatomycoses
264. Aluminum chloride in the treatment of symptomatic athlete's foot
265. Two-week oral treatment of tinea pedis comparing terbinafine (250 mg/day) with itraconazole (100 mg/day): A double-blind, multicentre study
266. Biometrological assessment of the preventive effect of a miconazole spray powder on athelete's foot
267. Safety of oral terbinafine for toenail onychomycosis
268. The safety experience of itraconazole in the diabetic population: Randomized, open-label study of itraconazole capsules versus palliative care for onychomycosis of the toenail in diabetic patients
269. Safety of itraconazole in diabetic patients
270. Hendersonula toruloidea and Scytalidium hyalinum: Review and update
271. Onychomycosis associated with Onychocola canadensis: 10 Case reports and a review of the literature
272. Effect of grapefruit juice on pharmacokinetics of itraconazole in healthy subjects
273. Warfarin-fluconazole - I: Inhibition of the human cytochrome p450-dependent metabolism of warfarin by fluconazole: In vitro studies
274. Warfarin-fluconazole. II. A metabolically based drug interaction: In vivo studies
275. Warfarin-fluconazole - III: A rational approach to management of a metabolically based drug interaction
276. Onychomycosis - Treatment, relapse and re-infection
277. Relapses of onychomycosis after successful treatment with systemic antifungals: A three-year follow-up
278. Oral antifungal agents for onychomycosis
279. How often does oral treatment of toenail onychomycosis produce a disease-free nail? An analysis of published data
280. Oral terbinafine in the treatment of toenails onychomycosis: North American multicenter trial
281. The evolving role of itraconazole, fluconazole and terbinafine in the treatment of tinea capitis
282. Pediatric antifungal therapy
283. Pharmacologic basis for the treatment of tinea capitis
284. The epidemic of tinea capitis disproportionately affects school-aged African Americans
285. Treatment of tinea capitis with itraconazole
286. Tinea capitis: An overview with emphasis on management
287. Tinea capitis: Epidemiology, diagnosis, treatment and control
288. Ecology, epidemiology and diagnosis of tinea capitis
289. Tinea capitis
290. A double-blind, randomized, comparative trial of itraconazole versus terbinafine for 2 weeks in tinea capitis
291. Treatment of tinea capitis: Beyond griseofulvin
292. Treatment of tinea capitis
293. Overview of the use of terbinafine (Lamisil) in children
294. Hair diseases
295. Diagnosis and management of common tinea infections
296. Skin and wound infections: An overview
297. Superficial fungal infections
298. Fungal infections in children
299. Onychomycosis in children: Prevalence and management